Vascular dysplasia in neurofibromatosis type 2.
Ryan
Aisling M
AM
Department of Neurology, Royal College of Surgeons Ireland, Beaumont Hospital, Dublin, Ireland.
Hurley
Michael
M
Brennan
Paul
P
Moroney
Joan T
JT
D000293:Adolescent; D000925:Anticoagulants / Q000627:therapeutic use; D001037:Aphasia / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D002533:Cerebral Angiography; D002540:Cerebral Cortex / Q000098:blood supply / Q000473:pathology* / Q000503:physiopathology; D002544:Cerebral Infarction / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D006423:Hemianopsia / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008579:Meningioma / Q000209:etiology / Q000473:pathology / Q000601:surgery; D020768:Middle Cerebral Artery / Q000473:pathology* / Q000503:physiopathology*; D009154:Mutation / Q000235:genetics; D016518:Neurofibromatosis 2 / Q000150:complications* / Q000175:diagnosis / Q000235:genetics; D025581:Neurofibromin 2 / Q000235:genetics; D010291:Paresis / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome
D000925:Anticoagulants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D025581:Neurofibromin 2